These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15285886)

  • 1. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy.
    O'Donoghue J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):378-87. PubMed ID: 15285886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical aspects of radiation nephropathy.
    Breitz H
    Cancer Biother Radiopharm; 2004 Jun; 19(3):359-62. PubMed ID: 15285883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
    Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
    J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948.
    Verwijnen S; Capello A; Bernard B; van den Aardweg G; Konijnenberg M; Breeman W; Krenning E; de Jong M
    Cancer Biother Radiopharm; 2004 Jun; 19(3):285-92. PubMed ID: 15285875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compatibility of the linear-quadratic formalism and biologically effective dose concept to high-dose-per-fraction irradiation in a murine tumor.
    Otsuka S; Shibamoto Y; Iwata H; Murata R; Sugie C; Ito M; Ogino H
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1538-43. PubMed ID: 22115556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy.
    Dale R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):363-70. PubMed ID: 15285884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced renal toxicity of total body irradiation combined with radioimmunotherapy.
    Röttinger EM; Bartkowiak D; Bunjes D; Wennauer R; Dohr D
    Strahlenther Onkol; 2003 Oct; 179(10):702-7. PubMed ID: 14566479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age dependence of radiation nephropathy in the rat.
    Moulder JE; Fish BL
    Radiat Res; 1997 Mar; 147(3):349-53. PubMed ID: 9052682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients?
    Konijnenberg MW
    Cancer Biother Radiopharm; 2003 Aug; 18(4):619-25. PubMed ID: 14503958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concerning the health effects of internally deposited radionuclides.
    Raabe OG
    Health Phys; 2010 Mar; 98(3):515-36. PubMed ID: 20147792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal dosimetry in peptide radionuclide receptor therapy.
    Siegel JA; Stabin MG; Sharkey RM
    Cancer Biother Radiopharm; 2010 Oct; 25(5):581-8. PubMed ID: 20849308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal damage in the mouse: the response to very small doses per fraction.
    Joiner MC; Johns H
    Radiat Res; 1988 May; 114(2):385-98. PubMed ID: 3375433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiobiological modeling of combined targeted 131I therapy and total body irradiation for treatment of disseminated tumors of differing radiosensitivity.
    Amin AE; Wheldon TE; O'Donoghue JA; Barrett A
    Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):323-30. PubMed ID: 8407407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summary and perspectives on kidney dose-response to radionuclide therapy.
    Wessels B
    Cancer Biother Radiopharm; 2004 Jun; 19(3):388-90. PubMed ID: 15285887
    [No Abstract]   [Full Text] [Related]  

  • 16. Prophylaxis of experimental bone marrow transplant nephropathy.
    Cohen EP; Moulder JE; Fish BL; Hill P
    J Lab Clin Med; 1994 Sep; 124(3):371-80. PubMed ID: 8083580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of time-dose-relationships in therapeutic nuclear medicine applications on biological effectiveness of irradiation: consequences for dosimetry].
    Oehme L; Dörr W; Wust P; Kotzerke J
    Nuklearmedizin; 2008; 47(5):205-9. PubMed ID: 18852927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation.
    Lawton CA; Cohen EP; Murray KJ; Derus SW; Casper JT; Drobyski WR; Horowitz MM; Moulder JE
    Bone Marrow Transplant; 1997 Dec; 20(12):1069-74. PubMed ID: 9466280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dose-fractionation sensitivity of the kidney; assessment of viable tubule cross-sections at 19 months after X irradiation.
    Jen YM; Hendry JH
    Br J Radiol; 1993 Mar; 66(783):241-4. PubMed ID: 8472117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A theoretical radiobiological assessment of the influence of radionuclide half-life on tumor response in targeted radiotherapy when a constant kidney toxicity is maintained.
    Abou-Jaoudé W; Dale R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):308-21. PubMed ID: 15285877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.